Renovalo SpA (RNV) Notizie

lolol. You don't know what Sharp CEO is capable. The largest following on social media. This is up 100% in a month. Need to learn how to make good picks.

PLEASE LISTEN…You at driving me nuts! The part for the Apple foldable phone is called a “spline” I cringe every time it’s referred to as a “spleen” which is a body part for the storage of blood. Thanks

D-Wave Qubits 2025 - Cathy McGeoch, principal scientist (retired), D-Wave.

Cathy McGeoch, former principal scientist at D-Wave, delivered an insightful session on the critical examination of quantum benchmarking papers. The discussion provided attendees with the tools to properly eva

Hey, Stay Humble, you're the MOASS (Mother Of All Stupid Sh*ts).😬

yeah right Redspudder - MONI leaks - lolzzz

best check your 12/10/24 RJ announcement date for "material events" before looking like - well - you know - total BS...

imagizer.imageshack.com/v2/1600x1200q70/901/lYr0ag.png

Nov 26, 2024 · MONI Reggie Jackson j

I’m educated guessing, but the Maxim Group being the exclusive Underwriter for the $20,000,000 NioCorp payday had to buy all of the shares for 2.60 immediately, to be able to sell the shares, now and in the future at Market Price or discounted to its own clients

***

GVSI $1000000 soon 

You posted a while back that you heard rumblings of another extension. Still feeling that way?

According to the chart? Like, 7 or 8 times in 5 years. Past performance is no indication of future performance but...

You said the same thing in 2017......

Are you worried 😟 😨 😳.......

It was supposed to die with revocation........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 ὣ

Thank you for posting this penguin! Great points! I have been invested for several months and I own another penny stock that I have been invested now for several years. Investing is a long game no doubt. I will be selling eventually, but not before the parabolic spike. And ideally that could be mult

Why not?  I guess you are claiming that you are always right and post a question and you say I need therapy. That is what the board is for. 

It appears the market doesn't care one way or another...

Dangerous Idaho donuts...


https://scontent-sea1-1.xx.fbcdn.net/v/t39.30808-6/492207016_1114388657374551_3725532621254982748_n.jpg?_nc_cat=108&ccb=1-7&_nc_sid=833d8c&_nc_ohc=jKzUrwk6t6sQ7kNvwG593qJ&_nc_oc=AdlLRE8cPn7v9CWgHTh9YAlCJfLxKs1sIGY9H8RP9Cu8lnes5a0AhTdDdsVjssgDwQWQlPrNJ

KEGS is a SCAM and it's CEO is a WANNABE!


This is fun; I see why you do it on other people's boards.

just like to see a profit..

Whoever it is that's posting the BS  needs attention 

NWBO's short rate is not going support much of a short squeeze -- it's only about 3.75%. Pretty low for an OTC biotech.
Set aside funding?? What funding? Future vulture fund, likely convertible preferreds that NWBO won't be able to pay off so will become significant dilution??

Great message mcptrman! Have you noticed bashers have grown extremely desperate and stooped to new lows but hey they continue to provide nonstop hilarious entertainment every single day. Vast Tag going live this month and will steamroll bashers permanently! Rocket on launchpad starting Monday. Conse

A short squeeze is impossible, as there's never been any significant shorting of any kind, so.... but, hey, go with that fantasy. Might as well, as this sad story is damn near comatose.

🤔‼️interesting...AI Overview: Summary Table: Schwab, BitGo, and Hedera
https://www.perplexity.ai/search/charles-schwab-digital-assets-nfRlwH3LQdm4CT1zN3OXWA

see also
How might Bitgo and Hedera collaborate with Charles Schwab in the digital assets space

This will require patience everyone. These reverse mergers take time, they are not instant hitters. In other words, everyone wanting a quick in and out, is not going to get it. Everyone saying “this will go to .05-.10” is in for a big surprise, and I do beg for you to sell in that range so I can buy

Exactly, insane

Steady, Think again!!!

You posted:

If that was true, then you would expect 2-73 to have no effect. The DPZ would have all the docking sites occupied and 2-73 would never agonize the S1 receptor.

A bet that Anavex 2-73, blarcamesine, and donepezil were tak